UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011811
Receipt number R000013777
Scientific Title The effect of Esomeprazole to asthma control in asthma patients with GERD taking inhaled corticosteroid
Date of disclosure of the study information 2013/09/19
Last modified on 2013/09/20 16:03:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of Esomeprazole to asthma control in asthma patients with GERD taking inhaled corticosteroid

Acronym

The effect of PPI in asthmatics with GERD

Scientific Title

The effect of Esomeprazole to asthma control in asthma patients with GERD taking inhaled corticosteroid

Scientific Title:Acronym

The effect of PPI in asthmatics with GERD

Region

Japan


Condition

Condition

Bronchial asthma with gastroesophageal reflux disease(GERD)

Classification by specialty

Gastroenterology Pneumology Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of Esomeprazole (EPZ) to asthma control in asthmatics with GERD and the safety of EPZ.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change of %FEV1 12 weeks after the introduction of EPZ.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Asthmatics with GERD are treated with Esomeprazole (EPZ)(20mg) daily for 12 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

In patients with bronchial asthma, all of the following criteria was required for enrollment
(1)age:20 years or more
(2)receiving inhaled corticosteroid for at least 4 weeks
(3)diagnosed with GERD by Gerd Q or FSSG

Key exclusion criteria

(1)hypersensitivity to EPZ or other PPI
(2)treated with atazanavir sulfate
(3)hypersensitivity to drugs
(4)severe disease in liver, kidney, heart
(5)severe symptom in gastrointestinal tract(hematemesis, hemorrhagic stool, severe anemia, sudden weight loss)
(6)past history of gastrointestinal tract resection, vagotomy, lung resection
(7)in combination with other PPI or histamine H2 antagonist
(8)not treated with systemic steroid for 3 months before the enrollment
(9)decided to be unsuitable to enrollment by physician

Target sample size

70


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akihito Yokoyama

Organization

Kochi University School of Medicine

Division name

Department of Hematology and Respiratory Medicine

Zip code


Address

Kohasu, Oko-cho, Nankoku, Kochi

TEL

088-880-2345

Email

ayokoyama@kochi-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shintaro Miyamoto

Organization

Kochi University School of Medicine

Division name

Department of Hematology and Respiratory Medicine

Zip code


Address

Kohasu, Oko-cho, Nankoku, Kochi

TEL

088-880-2345

Homepage URL


Email

miyamoto@kochi-u.ac.jp


Sponsor or person

Institute

Department of Hematology and Respiratory Medicine in Kochi University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Hematology and Respiratory Medicine in Kochi University School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

高知大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2013 Year 09 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2013 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 03 Month 01 Day

Last follow-up date

2014 Year 05 Month 31 Day

Date of closure to data entry

2014 Year 05 Month 31 Day

Date trial data considered complete

2014 Year 06 Month 30 Day

Date analysis concluded

2014 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2013 Year 09 Month 19 Day

Last modified on

2013 Year 09 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013777


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name